Global Life Science Partnering, Commercialization and Transactions

Back Bay has built a strong track-record and high-profile presence in Europe with project execution experience and contacts across the Nordics, the UK, France, Belgium, the Netherlands, Germany, Switzerland and Italy.

Globally, our advisors have nurtured relationships with all major biopharma and venture capital groups. The Boston-based imprimatur is sought by VCs and their portfolio companies who value transatlantic credentials.

As of 2023, Back Bay entered into a new strategic partnership with DNB Bank of Oslo, Norway. The DNB // Back Bay Partnership provides strategic advisory and investment banking capabilities to global biopharma, medtech, healthtech, diagnostic and healthcare service companies, ranging from pre-clinical startups to global multinationals. 

Back Bay specializes in US-EU life sciences partnerships, with emphasis on the Nordic region. We have completed dozens of strategy and investment banking projects with Nordic organizations and we provide supportive work for Nordic events, such as the Nordic American Life Science Conference, the Nordic Mentor Network for Entrepreneurship (NOME), Nordic Life Science Days, Nordic AMPlify and our own Nordic Growth Summit. Back Bay serves as partners to leading Nordic organizations including The Life Science Cluster (Norway) and The BioInnovation Institute Foundation (BII), an international non-profit supported by the Novo Nordisk Foundation (Denmark).

Our strategy and investment banking experts work extensively in all stages and sectors, with a variety of companies backed by leading Nordic funds. Strategy and transaction clients include a broad spectrum of dominant Nordic biotech, pharmaceutical and medtech/healthtech companies and their investors.

We believe that, like the US, the Nordic life science ecosystem represents best-in-class life science management, technology and financial expertise and excellence. We are proud of our long-standing collaborations and partnerships in the region.

 

Global PARTNERS:

 
 
 
AdobeStock_218597349.jpeg

Relationships with Worldwide Biopharma and Venture Capital Groups

 
 
report.png

Acesion Pharma Case Study

Venture-backed Danish biotech requested Back Bay support to define the optimal strategic roadmap to value creation for its novel cardiovascular drug in early stage development

APPROACH

Define the current development, clinical and commercial opportunity/positioning for the client’s program

  • Fully characterize the opportunity in the lead indication by considering the current and evolving market, current and emerging treatment paradigm, potential competitive therapies, adoption and regulatory hurdles, and commercial factors such as pricing, access and reimbursement
  • Also consider the regulatory and commercial hurdles for expansion into relevant adjacent patient populations and markets

Develop a commercial forecast with multiple adoption scenarios

  • Develop these insights into a disciplined “bottoms-up” commercial forecast including potential scenarios to elucidate revenue potential based on patient segment selection or market dynamics

Use multiple methodologies to understand a base and upside valuation, partnership timing, and investment implications

  • Develop a detailed precedent transaction analyses and scenario-based rNPV model to inform optimal internal investment strategies as well as partnering/strategic investment/acquisition approaches
  • Use comparable precedent transactions to understand potential timing and deal structure for potential partnerships

RESULT

Recommended the optimal strategy for driving differentiation of the program in a highly competitive market. Defined key value inflection points and associated required investment.

Back Bay is currently supporting ongoing licensing discussions for the client with large biopharma.